HRP20160495T1 - Morfolinilbenzotriazini za uporabu u terapiji raka - Google Patents

Morfolinilbenzotriazini za uporabu u terapiji raka Download PDF

Info

Publication number
HRP20160495T1
HRP20160495T1 HRP20160495TT HRP20160495T HRP20160495T1 HR P20160495 T1 HRP20160495 T1 HR P20160495T1 HR P20160495T T HRP20160495T T HR P20160495TT HR P20160495 T HRP20160495 T HR P20160495T HR P20160495 T1 HRP20160495 T1 HR P20160495T1
Authority
HR
Croatia
Prior art keywords
atoms
hal
image
denotes
tautomers
Prior art date
Application number
HRP20160495TT
Other languages
English (en)
Croatian (hr)
Inventor
Werner Mederski
Thomas Fuchss
Ulrich Emde
Hans-Peter Buchstaller
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of HRP20160495T1 publication Critical patent/HRP20160495T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D253/00Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/081Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/10Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20160495TT 2011-11-18 2012-10-30 Morfolinilbenzotriazini za uporabu u terapiji raka HRP20160495T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102011118830A DE102011118830A1 (de) 2011-11-18 2011-11-18 Morpholinylbenzotriazine
EP12783121.2A EP2780332B1 (de) 2011-11-18 2012-10-30 Morpholinylbenzotriazine zur anwendung in der krebstherapie
PCT/EP2012/004542 WO2013072015A1 (de) 2011-11-18 2012-10-30 Morpholinylbenzotriazine zur anwendung in der krebstherapie

Publications (1)

Publication Number Publication Date
HRP20160495T1 true HRP20160495T1 (hr) 2016-06-03

Family

ID=47143824

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20160495TT HRP20160495T1 (hr) 2011-11-18 2012-10-30 Morfolinilbenzotriazini za uporabu u terapiji raka

Country Status (24)

Country Link
US (1) US9187469B2 (OSRAM)
EP (1) EP2780332B1 (OSRAM)
JP (1) JP6096792B2 (OSRAM)
KR (1) KR20140097391A (OSRAM)
CN (1) CN103930408B (OSRAM)
AU (1) AU2012339196B2 (OSRAM)
BR (1) BR112014011805A2 (OSRAM)
CA (1) CA2856103C (OSRAM)
DE (1) DE102011118830A1 (OSRAM)
DK (1) DK2780332T3 (OSRAM)
EA (1) EA201400595A1 (OSRAM)
ES (1) ES2572605T3 (OSRAM)
HK (1) HK1199875A1 (OSRAM)
HR (1) HRP20160495T1 (OSRAM)
HU (1) HUE027577T2 (OSRAM)
IL (1) IL232577A (OSRAM)
IN (1) IN2014KN01287A (OSRAM)
MX (1) MX2014005838A (OSRAM)
PL (1) PL2780332T3 (OSRAM)
RS (1) RS54768B1 (OSRAM)
SG (1) SG11201402206YA (OSRAM)
SI (1) SI2780332T1 (OSRAM)
WO (1) WO2013072015A1 (OSRAM)
ZA (1) ZA201404438B (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS61664B1 (sr) 2012-04-24 2021-04-29 Vertex Pharma Inhibitori dna-pk
SI3527563T1 (sl) 2013-03-12 2022-01-31 Vertex Pharmaceuticals Incorporated Inhibitorji DNA-PK
DE102013008118A1 (de) 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
SI3424920T1 (sl) 2013-10-17 2020-08-31 Vertex Pharmaceuticals Incorporated Kokristali (s)-n-metil-8-(1-((2'-metil-(4,5'-bipirimidin)-6-il)amino)propan-2-il) kinolin-4-karboksamida in devterirani derivati le-teh kot inhibitorji dna-pk
KR20190062485A (ko) 2016-09-27 2019-06-05 버텍스 파마슈티칼스 인코포레이티드 Dna-손상제 및 dna-pk 저해제의 조합을 사용한 암 치료 방법
CN107793373B (zh) * 2017-10-31 2019-09-17 广西师范大学 2-取代苯并三嗪酮衍生物及其制备方法
US12121524B2 (en) 2018-01-17 2024-10-22 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
ES2980444T3 (es) 2018-01-17 2024-10-01 Vertex Pharma Inhibidores de ADN-PK
CN111770921B (zh) 2018-01-17 2024-03-22 沃泰克斯药物股份有限公司 用于提高基因组编辑效率的喹喔啉酮化合物,组合物,方法和试剂盒
AU2020372700A1 (en) 2019-11-01 2022-05-12 Syngenta Crop Protection Ag Pesticidally active fused bicyclic heteroaromatic compounds
CR20240002A (es) 2021-06-24 2024-02-13 Syngenta Crop Protection Ag Derivados de 2-[3-[1 [(quinazolin-4-il)amino]etil]pirazin-2-il]tiazol-5-carbonitrilo y compuestos similares como plaguicidas
EP4543873A1 (en) 2022-06-21 2025-04-30 Syngenta Crop Protection AG Pesticidally active fused bicyclic heteroaromatic compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT64533A (en) 1990-11-06 1994-01-28 Pfizer Method for producing quinazoline derivatives for improving anti-tumoric activity and preparations containing said compounds
AU4972900A (en) 1999-04-08 2000-11-14 Arch Development Corporation Use of anti-vegf antibody to enhance radiation in cancer therapy
WO2002020500A2 (en) 2000-09-01 2002-03-14 Icos Corporation Materials and methods to potentiate cancer treatment
US7291733B2 (en) * 2003-10-10 2007-11-06 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted tricyclic heterocycles and their uses
CN101230045B (zh) * 2008-02-14 2013-04-10 沈阳药科大学 芳环并三嗪类衍生物及其应用
WO2011113512A1 (de) * 2010-03-16 2011-09-22 Merck Patent Gmbh Morpholinylchinazoline

Also Published As

Publication number Publication date
EP2780332B1 (de) 2016-02-24
US20140275072A1 (en) 2014-09-18
JP2015502926A (ja) 2015-01-29
IN2014KN01287A (OSRAM) 2015-10-16
US9187469B2 (en) 2015-11-17
HK1199875A1 (en) 2015-07-24
HUE027577T2 (en) 2016-10-28
CN103930408B (zh) 2016-09-07
SG11201402206YA (en) 2014-11-27
WO2013072015A1 (de) 2013-05-23
RS54768B1 (sr) 2016-10-31
EA201400595A1 (ru) 2014-11-28
MX2014005838A (es) 2014-07-30
IL232577A (en) 2017-05-29
JP6096792B2 (ja) 2017-03-15
IL232577A0 (en) 2014-06-30
DE102011118830A1 (de) 2013-05-23
DK2780332T3 (en) 2016-05-30
ZA201404438B (en) 2015-12-23
CA2856103C (en) 2020-08-25
ES2572605T3 (es) 2016-06-01
AU2012339196B2 (en) 2017-04-27
CA2856103A1 (en) 2013-05-23
PL2780332T3 (pl) 2016-07-29
BR112014011805A2 (pt) 2017-05-16
SI2780332T1 (sl) 2016-06-30
CN103930408A (zh) 2014-07-16
AU2012339196A1 (en) 2014-07-03
EP2780332A1 (de) 2014-09-24
KR20140097391A (ko) 2014-08-06

Similar Documents

Publication Publication Date Title
HRP20160495T1 (hr) Morfolinilbenzotriazini za uporabu u terapiji raka
HRP20150489T1 (hr) Imidazo[4,5-c]kinolini kao inhibitori dna-pk
JP6789239B2 (ja) Krasの縮合三環系インヒビターおよびその使用の方法
JP6862495B2 (ja) Jak及びpi3k阻害剤併用によるb細胞悪性腫瘍の処置
HRP20150030T1 (hr) Derivati pirazolokinolina kao inhibitori dna-pk
HRP20231276T1 (hr) Inhibitor egfr-a za liječenje raka
MX2009008953A (es) Compuestos como inhibidores de angiogenesis.
NZ630457A (en) Compounds useful as inhibitors of atr kinase
EA201201289A1 (ru) Морфолинилхиназолины
HRP20220886T1 (hr) Pripravci i postupci za proizvodnju pirimidina i spojeva piridina s btk inhibicijskom aktivnošću
ES2910071T3 (es) Compuestos de aminopirazina diol como inhibidores de PI3K-Y
AR073551A1 (es) Pirimidinas macrociclicas como inhibidores de proteina cinasa
JP2013529196A5 (OSRAM)
JP2014503567A5 (OSRAM)
BR112013014184A2 (pt) compostos de triazina [1,2,4] triazolo [4,3-b][1,2,4], método de preparo e seu uso
NZ588830A (en) Inhibitors of protein kinases
JP2013510120A5 (OSRAM)
MX2013008296A (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
WO2010021918A8 (en) Compounds as kinase inhibitors
PE20230372A1 (es) Triazolopirimidinas como inhibidores de a2a/a2b
BR112015023705A2 (pt) composto da fórmula (ia) ou um sal, hidrato, solvato ou forma cristalina farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composto e método para síntese do composto da fórmula (ia)
JP2018062526A (ja) mTOR経路関連疾患を治療するための化合物
HRP20211801T1 (hr) Derivati kinolin-2-ona
JP2022136163A (ja) Dna損傷剤とdna-pk阻害剤との組合せ物を使用する、がんを処置するための方法
CN116947764B9 (zh) 一种嘧啶胺类nuak抑制剂及其制备方法和用途